FY2024 Earnings Forecast for CRBU Issued By Leerink Partnrs

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Leerink Partnrs increased their FY2024 earnings estimates for Caribou Biosciences in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.69) per share for the year, up from their prior forecast of ($1.77). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.71) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ Q4 2024 earnings at ($0.42) EPS, FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($1.69) EPS and FY2028 earnings at ($0.52) EPS.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million.

A number of other equities analysts also recently weighed in on CRBU. Royal Bank of Canada reiterated an “outperform” rating and issued a $14.00 target price on shares of Caribou Biosciences in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Tuesday, September 3rd.

Caribou Biosciences Trading Down 15.9 %

NASDAQ:CRBU opened at $2.35 on Monday. Caribou Biosciences has a 1-year low of $1.50 and a 1-year high of $8.33. The firm has a market capitalization of $212.34 million, a price-to-earnings ratio of -1.58 and a beta of 2.26. The business’s fifty day moving average price is $2.02 and its 200 day moving average price is $2.27.

Institutional Investors Weigh In On Caribou Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in shares of Caribou Biosciences by 9.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 42,653 shares of the company’s stock valued at $219,000 after buying an additional 3,594 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Caribou Biosciences by 32.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 230,192 shares of the company’s stock worth $1,097,000 after acquiring an additional 56,586 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Caribou Biosciences during the 1st quarter worth $558,000. Entropy Technologies LP bought a new position in shares of Caribou Biosciences during the 1st quarter valued at $113,000. Finally, Vanguard Group Inc. raised its holdings in shares of Caribou Biosciences by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company’s stock valued at $21,129,000 after purchasing an additional 148,751 shares in the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.